CANDEL THERAPEUTICS, INC. Increase (Decrease) in Other Operating Assets
CANDEL THERAPEUTICS, INC. (CADL) reported Increase (Decrease) in Other Operating Assets of $11.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was -$10.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $21.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was $2.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was $40.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for fiscal 2025 was $24.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for fiscal 2024 was -$53.00K, a 145.69% decline from fiscal 2023.
- CANDEL THERAPEUTICS, INC. increase (decrease) in other operating assets for fiscal 2023 was $116.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $11.00K 10-Q · filed 2026-08-13 | $13.00K derived: sum of 3 quarters · filed 2026-08-13 | $53.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $21.00K 10-Q · filed 2026-05-14 | $23.00K derived: sum of 2 quarters · filed 2026-05-14 | $63.00K derived: sum of 3 quarters · filed 2026-05-14 | $50.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $42.00K derived: sum of 2 quarters · filed 2026-03-12 | $29.00K derived: sum of 3 quarters · filed 2026-08-13 | $24.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $27.00K derived: sum of 2 quarters · filed 2026-08-13 | $22.00K 10-Q · filed 2025-11-13 | $10.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$18.00K 10-Q · filed 2026-08-13 | -$30.00K derived: sum of 3 quarters · filed 2026-08-13 | -$36.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$5.00K 10-Q · filed 2026-05-14 | -$17.00K derived: sum of 2 quarters · filed 2026-05-14 | -$23.00K derived: sum of 3 quarters · filed 2026-05-14 | -$44.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$18.00K derived: sum of 2 quarters · filed 2026-03-12 | -$39.00K derived: sum of 3 quarters · filed 2026-03-12 | -$53.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$27.00K derived: sum of 2 quarters · filed 2025-11-13 | -$41.00K 10-Q · filed 2025-11-13 | -$64.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$35.00K 10-Q · filed 2025-08-14 | -$58.00K derived: sum of 3 quarters · filed 2025-08-14 | -$78.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$14.00K 10-Q · filed 2025-05-13 | -$37.00K derived: sum of 2 quarters · filed 2025-05-13 | -$57.00K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$43.00K derived: sum of 2 quarters · filed 2025-03-13 | $116.00K 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $139.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $159.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |